Poster Abstract Session:
155. HIV: Antiretroviral Therapy
Friday, October 28, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Tracks: Trainee, Pediatric ID, HIV-STD-TB, Adult ID

Presentations:
1508
Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 48: Subgroup Analysis of a Randomized Switch Study
Edwin Dejesus, MD ; Richard Elion, MD ; Moti Ramgopal, MD, FACP, FIDSA ; Barbara H. Wade, MD, FIDSA ; Louis Sloan, MD ; Howard Edelstein, MD ; Gerald Pierone Jr., MD ; Jihad Slim, MD ; Jeffrey Stephens, MD ; Mingjin Yan, PhD ; Cecilia Tran-Muchowski, BS ; Martin Rhee, MD
Posters
  • DeJesus IDWeek 2016 Poster 1508.pdf (2.2 MB)
    • 1509
    Emergence of HIV-1 Drug Resistance Through Week 48 in the Global Women’s WAVES Study: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs. Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF
    Rima Kulkarni, BS ; Sally Hodder, MD ; Huyen Cao, MD ; Silvia Chang, MS ; Michael Miller, PhD ; Kirsten White, PhD
    Posters
  • Kulkarni WAVES Study IDWeek 2016 Poster 1509_Final.pdf (389.9 kB)
    • 1510
    The HLA-B*53 / HLA-C*04 Haplotype is Strongly Associated with DRESS Syndrome during Treatment with Raltegravir.
    Mark Thomas, MD ; Christopher Hopkins, MD ; Eamon Duffy, MPharm ; Pierre Loulergue, MD ; Diego Ripamonti, MD ; Daniel Lee, MD
    Posters
  • DRESS Raltegravir HLAB53 IDSA New Orleans final poster.pdf (2.8 MB)
    • 1511
    Clinically Significant Drug Interactions Among HIV Positive Outpatients on Antiretroviral Therapy
    Lea Monday, PharmD, MD Candidate 2016 ; Alison Van Dyke, MD, PhD ; Jennifer Veltman, MD
    1512
    The Impact of Antiretroviral Tablet Burden and Polypharmacy on Viral Suppression in Treatment Naïve Patients
    Anthony Mills, MD ; Jennifer Fusco, BS ; Kathy Schulman, MA ; Cassidy Henegar, PhD, MSPH ; Susan Zelt, DrPH, MBA ; Ronald D' Amico, DO, MSc ; Felix Carpio, MD, MPH
    Posters
  • IDWeek Poster #4 Layout Revised Final.pdf (462.4 kB)
    • 1513
    Cabotegravir(CAB) Safety Meta-analysis Update from 14 Phase I/IIa Studies
    Yu Lou, MS ; Elizabeth Gould, BS ; Caifeng Fu, MS ; Allan Tenorio, MD ; William Spreen, PharmD ; Parul Patel, PharmD ; David Margolis, MD, MPH
    Posters
  • IDWeek 2016_Lou_1513.pdf (324.2 kB)
    • 1514
    Actual versus perceived use of pharmacokinetic (primarily absorption) influential OTC agents and ART tolerability in a nationwide matched cohort of HIV patients and their healthcare providers
    Mark Gehrig, PharmD Candidate ; Patrick Clay, Pharm.D, AAHIVP, CPI, CCTI, FCCP ; Richard Perry, BSc ; Anna Hadfield, MChem ; Jialiang Liu, BS, MS ; Sumihiro Suzuki, Ph.D.
    Posters
  • HIV-Survey IDWeek 2016 - 36X72 Approved proof.pdf (401.9 kB)
    • 1515
    Prevalence and Reasons of Antiretroviral Therapy (ART) Switch Among HIV Patients in a large Urban Center
    Mohammed Shaikhomer, MD ; Abdulhadi Gelaidan, MD, MPH ; Hatim Batawi, MD, MSPH ; Katelin Snow, Medical Student ; Alison Payson, Medical Student ; Nafeesa Chin-Beckford, PharmD ; Luis Espinoza, MD
    Posters
  • Slide1.jpg (168.8 kB)
    • 1516
    Characteristics of Treatment-Experienced HIV-1-Infected Patients Switching from Multi-Tablet to Single-Tablet Regimens in the Veterans Affairs Health Care System
    Maral Dersarkissian, PhD ; Kathy Schulman, MA ; Susan Zelt, DrPH, MBA ; Ronald D’Amico, DO, MSc ; Rachel Bhak, MS, BS ; Michael Hellstern, BA ; Antonia Altomare, DO, MPH ; Ellyn Ercolano, MS ; Mei Sheng Duh, ScD, MPH ; Yinong Young-Xu, ScD, MS, MA
    1517
    Variability in Population Characteristics among HIV+ ART-Naïve Patients Initiating on Single Tablet Regimens
    George Melikian, MD, MPH ; Jennifer Fusco, BS ; Kathy Schulman, MA ; Cassidy Henegar, PhD, MSPH ; Susan Zelt, DrPH, MBA ; Ronald D' Amico, DO, MSc ; Philip Lackey, MD
    Posters
  • IDWeek Poster #3 Layout Final.pdf (436.9 kB)
    • 1518
    Monitoring Viral Suppression When Switching from Fixed Dose Combination Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate (Atripla) to Fixed Dose Combination Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate (Stribild) in Virologically Suppressed Adults with HIV
    Edward Braun, MD
    Posters
  • 1518 IDWeek Web Upload.png (1.0 MB)
    • 1519
    Dolutegravir 50 mg + Rilpivirine 25 mg (DTV+RPV) Daily in Treatment-Experienced HIV-Infected Patients
    Christopher Saling, MD ; Maria Elaine Szabela, MD ; Melinda Brown, MD ; Tamara Johnson, MD ; Raymund Sison, MD ; Jihad Slim, MD
    Posters
  • poster_DTV+RPV_FINAL.pdf (756.2 kB)
    • 1520
    Does Slow Efavirenz Metabolism Have Greater Impact on Outcomes of Older HIV+ Africans?
    Jessie Torgersen, MD, MHS ; Athena Zuppa, MD, MSCE ; Scarlett Bellamy, ScD ; Xiaoyan Han, MS ; Gregory P. Bisson, MD, MSCE ; Robert Gross, MD, MSCE
    Posters
  • Torgersen_Poster 1520_IDWeek 2016.pdf (356.9 kB)
    • 1521
    Risk Factors for Low Immune Recovery Among Participants with CD4+ Counts > 500 cells/mm3 who Achieved Viral Suppression in the Immediate Antiretrovrial Treatment (ART) Group in Strategic Timing of AntiRetroviral Treatment (START) Trial
    Jeffrey Boatman, M.S. ; Jason Baker, MD ; Sean Emery, PhD ; David Mushatt, MD, MPH & TM, FIDSA ; Hansjakob Furrer, M.D. ; Dalibor Sedláček, MD., PhD. ; Jens Lundgren, MD, D.M.Sc, Professor ; James Neaton, PhD
    Posters
  • boatman_poster.pdf (2.4 MB)
    • 1522
    Switching Undetectables to Once Daily Selzentry®: The SUDS Study
    Stanley Lewis, MD ; Kenneth Degazon, MD ; Chymbeelyn Larisma, MD ; Katherine Asuncion, MD
    Posters
  • The SUDS Poster_ID Week 2016.pdf (199.5 kB)

    • CME Credits: No CME credit is offered for this session.

    ACPE Credits:

    ACPE Number:


    See more of: Poster Abstract Session
    << Previous Session | Next Session >>

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.